Your browser doesn't support javascript.
loading
US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma.
Matasar, Matthew; Masaquel, Anthony; S Ho, Rodrigo; Launonen, Aino; Ng, Carmen D; Wang, Rongrong; Fox, David; Hossain, Farah; Li, Jia; Burke, John M.
Affiliation
  • Matasar M; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA.
  • Masaquel A; Genentech, Inc, South San Francisco, CA, USA.
  • S Ho R; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Launonen A; F. Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Ng CD; Genentech, Inc, South San Francisco, CA, USA.
  • Wang R; Genentech, Inc, South San Francisco, CA, USA.
  • Fox D; Genentech, Inc, South San Francisco, CA, USA.
  • Hossain F; Genentech, Inc, South San Francisco, CA, USA.
  • Li J; Genentech, Inc, South San Francisco, CA, USA.
  • Burke JM; Rocky Mountain Cancer Centers/US Oncology, Aurora, CO, USA.
J Med Econ ; 26(1): 1134-1144, 2023.
Article in En | MEDLINE | ID: mdl-37674384
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Cost-Effectiveness Analysis Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: J Med Econ Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Lymphoma, Large B-Cell, Diffuse / Cost-Effectiveness Analysis Type of study: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: J Med Econ Year: 2023 Document type: Article